Securities and Exchange Commission v. Vivera Pharmaceuticals, Inc. et al

  1. November 25, 2025

    Judge Hands SEC Win In Pharma Co.'s CBD Investor Fraud Case

    A California federal judge has granted the U.S. Securities and Exchange Commission an early win in its suit against Vivera Pharmaceuticals, its CEO and affiliate Sentar Pharmaceuticals, finding they misled investors about the company's rights to key cannabinoid drug-delivery technology and about how investor money would be spent.

  2. October 23, 2025

    SEC Being Misled In CBD Fraud Fight, CEO Claims

    The U.S. Securities and Exchange Commission has "unwittingly" taken the side of a former partner with a terminated licensing agreement, a pharmaceutical CEO told a California federal court this week, asking for summary judgment on the SEC's core claims that he defrauded investors.

  3. October 03, 2022

    Pharma Co. Lied About CBD License To Investors, SEC Says

    The U.S. Securities and Exchange Commission is going after a pair of pharmaceutical companies that it says lied to potential investors about having exclusive rights to a method for taking CBD under the tongue in order to collect $6.6 million.